Transforming growth factor-b (TGF-b) is known to regulate chondrocyte proliferation and hypertrophic differentiation in embryonic bone cultures by a perichondrium dependent mechanism. To begin to determine which factors in the perichondrium mediate the effects of TGF-b, we studied the effect of Insulin-like Growth Factor-1 (IGF-I) and Fibroblast Growth Factors-2 and -18 (FGF2, FGF18) on metatarsal organ cultures. An increase in chondrocyte proliferation and hypertrophic differentiation was observed after treatment with IGF-I. A similar effect was seen after the perichondrium was stripped from the metatarsals suggesting IGF-I acts directly on the chondrocytes. Treatment with FGF-2 or FGF-18 resulted in a decrease in bone elongation as well as hypertrophic differentiation. Treatment also resulted in a decrease in BrdU incorporation into chondrocytes and an increase in BrdU incorporation in perichondrial cells, similar to what is seen after treatment with TGF-b1. A similar effect was seen with FGF2 after the perichondrium was stripped suggesting that, unlike TGF-b, FGF2 acts directly on chondrocytes to regulate proliferation and hypertrophic differentiation. To test the hypothesis that TGF-b regulates IGF or FGF signaling, activation of the receptors was characterized after treatment with TGF-b. Activation was measured as the level of tyrosine phosphorylation on the receptor. Treatment with TGF-b for 24 h did not alter the level of IGFR-I tyrosine phosphorylation. In contrast, treatment with TGF-b resulted in and increase in tyrosine phosphorylation on FGFR3 without alterations in total FGFR3 levels. TGF-b also stimulated expression of FGF18 mRNA in the cultures and the effects of TGF-b on metatarsal development were blocked or partially blocked by pretreatment with FGF signaling inhibitors. The results suggest a model in which FGF through FGFR3 mediates some of the effects of TGF-b on embryonic bone formation.
Introduction
Endochondral bone formation involves the formation of a cartilaginous template and its subsequent replacement by osteoblasts to form bone (Cancedda et al., 1995) . The regulation of chondrocyte growth and differentiation during this process is critical for proper skeletal development.
Defects in regulation of this process can lead to disorders in skeletal morphogenesis. Endochondral bone formation is regulated by multiple mechanisms including factors emanating from the surrounding matrix, oxygen supply, inflammatory mediators, cytokines, and various growth factors. Transforming growth factor-beta (TGF-b), insulinlike growth factor-1 (IGF-1) and fibroblast growth factors (FGFs) are important growth factors in bone and their functions and interactions at various stages of bone development control the pace of chondrocyte differentiation.
The members of the TGF-b super family are secreted signaling molecules that regulate many aspects of growth and differentiation (reviewed in Massague, 1998; Moses and Serra, 1996; Roberts and Sporn, 1990; Serra and Chang, 2003) . Members of the TGF-b superfamily are expressed in embryonic and adult skeletal tissue (Gatherer et al., 1990; Heine et al., 1987; Millan et al., 1991; Pelton et al., 1990 Pelton et al., , 1991 Sandberg et al., 1988) . TGF-b promotes chondrogenesis in early-undifferentiated mesenchymal cells (Denker et al., 1994; Leonard et al., 1991) but inhibits hypertrophic differentiation in mature cultures (Ballock et al., 1993; Bohme et al., 1995; Kato et al., 1988; Serra et al., 1999; Tschan et al., 1993) . TGF-b inhibits both growth and hypertrophic differentiation in embryonic metatarsal cultures in a perichondrium dependent manner (Alvarez et al., 2001 (Alvarez et al., , 2002 . Previous findings using chick tibiotarsus cultures showed that the perichondrium can elaborate signals that negatively regulate both chondrocyte proliferation and differentiation (Di Nino et al., 2001; Long and Linsenmayer, 1998) . Parathyroid Hormone (PTH) was shown to prevent increased differentiation resulting from removal of the perichondrium and our previous results indicated that TGF-b regulated hypertrophic differentiation through PTHrP (Long and Linsenmayer, 1998; Serra et al., 1999) . The mechanism of TGF-b mediated growth inhibition through perichondrium was not addressed. It is likely one or more factors in the perichondrium are involved.
Several factors have been shown to regulate chondrocyte proliferation in vivo. The most well characterized effects are those of FGF and IGF. Fibroblast Growth Factor Receptor 3 (FGFR3) is expressed in chondrocytes in the proliferating zone (Deng et al., 1996; Peters et al., 1993) . The association of Fgfr3 mutations in human dwarfing conditions and results from genetically altered mice clearly show a role for FGF and specifically FGFR3 in negatively regulating chondrocyte growth (reviewed in Coumoul and Deng, 2003; . Fgfr3-null mice demonstrate skeletal overgrowth (Colvin et al., 1996; Deng et al., 1996) while mice with an activating mutation in Fgfr3 (Fgfr3
G380R
) demonstrate dwarfism as a result of reduced chondrocyte proliferation . Other activating mutations of Fgfr3 (Fgfr3 G375C and Fgfr3 K650E ) also cause inhibition of both proliferation and differentiation of chondrocytes resulting in retarded bone growth Li et al., 1999) . Mice with Fgfr3-K644E mutation (analogues to human thanatophoric dysplasia type II) and Fgfr3-K644M mutation (analogues to human severe achondroplasia with developmental delay and acanthosis nigricans, SADDAN mutation) also show dwarfism due to defective long bone development (Iwata et al., 2000 (Iwata et al., , 2001 .
FGFR1 and FGFR2 are expressed in the perichondrium and FGFR1 is also expressed in the hypertrophic chondrocytes unlike FGFR3, which is mainly expressed in proliferating chondrocytes (Delezoide et al., 1998; Orr-Urtreger et al., 1991; Peters et al., 1992 Peters et al., , 1993 . The exact role of FGFR1 and FGFR2 in endochondral bone formation is not clear. Mutations in Fgfr-1 and -2 are associated mainly with the craniosynostosis syndromes, with some appendicular skeleton defects (Burke et al., 1998; Wilke et al., 1997) .
Misexpression of FGF2 or FGF9 in chondrocytes also results in skeletal dysplasia primarily due to reduced chondrocyte proliferation (Coffin et al., 1995; Garofalo et al., 1999) . In addition, the total length and hypertrophic area is reduced in embryonic rodent bones in organ culture treated with FGF2 (Chen et al., 2001; Mancilla et al., 1998) . Recently, it was suggested that FGF18 is the endogenous ligand of FGFR3 in prehypertrophic chondrocytes (Liu et al., 2002; Ohbayashi et al., 2002) . Mice with targeted deletion of Fgf18 demonstrate increased proliferation, similar to what is observed in Fgfr3-null mice. Furthermore, FGF18 is expressed in the perichondrium adjacent to FGFR3 in prehypertrophic chondrocytes suggesting paracrine interactions regulate chondrocyte proliferation in vivo. FGFR3 may also directly or indirectly regulate hypertrophic differentiation (Chen et al., 2001; . This response is separate and independent of PTHrP (Chen et al., 2001) .
Insulin-like Growth Factors (IGF-I and IGF-II) stimulate proliferation in chondrocytes (reviewed in Dupont and Holzenberger, 2003; Schmid, 1995) . IGFs stimulate longitudinal growth in rat neonatal metatarsal cultures (Coxam et al., 1995 (Coxam et al., , 1996 and targeted disruption of Igf1, Igf2, or Igf1r results in dwarfism (Liu et al., 1993) . IGF-I and IGF-II mRNA have been localized to the perichondrium in developing long bones (Beck et al., 1988; Han et al., 1987) and the receptors are concentrated in chondrocytes and osteoblasts throughout skeletal development (Wang et al., 1995) . The activity of IGF is controlled by a family of extracellular binding proteins, IGFBP1 through IGFBP6. IGFBPs are differentially expressed in a variety of tissues and cell types. All six IGFBPs are expressed in bone and modulate IGF bioavailability. The expression pattern of IGFBPs has been characterized in growth plate chondrocytes (Wang et al., 1995) but expression in the perichondrium has been largely overlooked and has only been reported for IGFBP6 (Van Kleffens et al., 1998) . TGF-b has been shown to regulate expression of IGFs, IGF receptor, and IGFBPs in many cell types including chondrocytes (de Los Rios and Hill, 2000; Kveiborg et al., 2001; Tsukazaki et al., 1994) .
We propose that factors from the perichondrium mediate the effects of TGF-b on endochondral bone development. To begin to determine which factors are involved in TGF-b mediated inhibition of endochondral bone formation, we test the effects of FGF2, which activates FGFR3 on chondrocytes, and IGF-I on intact and perichondrium-free metatarsal bones in organ culture. The results suggest FGF and IGF act directly on chondrocytes to regulate growth and hypertrophic differentiation. Next, we demonstrate that treatment with TGF-b stimulates phosphorylation of FGFR3 and general inhibitors of FGF signaling block or partially block the growth and differentiation effects of TGF-b on the organ cultures. The results suggest that TGFb can activate FGF signaling pathways during endochondral bone formation and that FGF signaling is at least partially required for the effects of TGF-b on metatarsal development. We then show that TGF-b stimulates expression of FGF18 making it a candidate target for TGF-b in the perichondrium.
Results
2.1. The effects of IGF-I and FGF2 on metatarsal development are mediated directly through chondrocytes TGF-b is known to regulate chondrocyte proliferation and hypertrophic differentiation in metatarsal organ cultures by a perichondrium dependent mechanism, suggesting the involvement of additional factors (Alvarez et al., 2001 (Alvarez et al., , 2002 . FGF and IGF are known mediators of chondrocyte proliferation (Coumoul and Deng, 2003; Dupont and Holzenberger, 2003) . We proposed a model in which TGF-b activates the FGF signaling pathway or downregulates the IGF pathway resulting in the reduction in total bone length and chondrocyte proliferation observed in TGFb treated organ cultures. Since the effects of TGF-b are dependent on the perichondrium, the first prediction of the model is that the effects of FGF or IGF on endochondral bone formation are due to direct action on chondrocytes. First, the effect of IGF-I or FGF2 on development in our organ culture model was determined. Metatarsal bones isolated from embryonic day 15.5 mice were either untreated or treated with 10, 30, and 100 ng/ml of IGF-I or FGF2 for 5 days (Fig. 1) . Treatment with 100 ng/ml or IGF-I or FGF2 gave the maximal response. Treatment with IGF-I resulted in an overall increase in the length of the bone while treatment with FGF2 resulted in a decrease in the total bone length as previously described (Fig. 1A -C,G; Coxam et al., 1996; Mancilla et al., 1998) .
Total bone length is a combination of changes in hypertrophic differentiation and proliferation during the development of the bone. As previously described, hypertrophic cartilage is seen as the clear area in the center of the organ culture (Dieudonne et al., 1994; Serra et al., 1999) . Hypertrophic differentiation was measured as the length of the clear area over the total length of the bone. The measurement normalizes for any differences in the total length of the bone. Treatment with IGF-1 resulted in an increase in the amount of hypertrophic cartilage in the culture and treatment with FGF2 resulted in a dramatic decrease (Fig. 1H) . The level of hypertrophic differentiation measured in this way correlated with the percentage of histologically hypertrophic cartilage observed in hematoxylin and eosin stained sections from each of the conditions tested (Fig. 1D,E ) and in the area of cartilage expressing Col10a mRNA (not shown).
Next, the effects of each factor on proliferation were measured as the percentage of cells that incorporated BrdU into their nucleus (Fig. 1I-L) . Treatment with IGF-I for 24 h resulted in an increase in labeled chondrocytes relative to untreated controls (Fig. 1L) . Treatment with FGF2 resulted in a decrease in the number of labeled chondrocyte nuclei; however, the number of labeled nuclei was increased in the perichondrium (Fig. 1K) . The effects of FGF2 on development of the metatarsal cultures mimicked the effects of TGF-b previously reported (Serra et al., 1999) . That is both TGF-b and FGF2 inhibit hypertrophic differentiation and chondrocyte proliferation while promoting proliferation in the perichondrium.
Next, the role of the perichondrium in IGF-I and FGF2 mediated effects on metatarsal development were determined (Fig. 2) . FGF and IGF ligands as well as IGFBPs have already been localized to the perichondrium (Beck et al., 1988; Han et al., 1987; Liu et al., 2002; Ohbayashi et al., 2002; Van Kleffens et al., 1998) while FGFR3 and IGFR1 are localized on prehypertrophic chondrocytes (Deng et al., 1996; Peters et al., 1993; Wang et al., 1995) . Metatarsal bones in which the perichondrium had been enzymatically removed were either untreated or treated with IGF-I or FGF2 for 5 days. The total length and hypertrophic area of the cultures was then measured (Fig. 2) . Treatment with IGF-I again resulted in an increase in the total length and hypertrophic area of the bone suggesting that the effects of IGF-I on chondrocytes are direct and not mediated through the perichondrium. Treatment with FGF2 resulted in a decrease in total length and hypertrophic area in the absence of the perichondrium suggesting that, unlike TGF-b, the effects of FGF2 on chondrocytes are direct.
TGF-b activates FGF signaling
If TGF-b acts through IGF or FGF we would expect that treatment with TGF-b would result in alterations in the activation state of the receptors. To test this hypothesis, metatarsal cultures were either untreated or treated with 10 ng TGF-b/ml for 24 h. Bones treated with either FGF2 or IGF-I were used as positive controls. IGFR1 phosphorylation was detected by Western blot using a phospho-IGFR1 specific antibody (Fig. 3) . The total level of IGFR1 beta subunit was also determined by Western blot. Alterations were not detected in the total level or phosphorylation state of the IGFR1 after treatment with TGF-b for 24 h (Fig. 3) ; however, a reduction in the total level of IGFR1 was detected after 5 days of treatment (not shown). FGFR3 was immunoprecipitated from protein extracts made from untreated and TGF-b treated metatarsals. Receptor phosphorylation was detected by anti-phosphotyrosine immunoblot. To control for the total receptor levels, receptor protein was detected in blots that were stripped of the anti-phosphotyrosine antibody and incubated with an antibody for FGFR3. Alterations were not detected in the total level of FGFR3 protein (Fig. 3 ). Little to no Fig. 1 . Effects of IGF-I and FGF2 on metatarsal bone development in organ culture. Metatarsal bones were cultured for 5 days in the absence (A) or presence of 100 ng IGF-I/ml (B), or 100 ng FGF2/ml (C). The total length of bones was measured and the means and standard deviations were calculated and graphed (G). Statistical significance was calculated using a Student's t-test. P-values less than 0.0001 are indicated with an asterisk. Bones that were untreated (D) or treated with IGF-I (E) or FGF2 (F) for 5 days were sectioned and stained with hematoxylin and eosin. The percent area of hypertrophic cartilage was measured and the means and standard deviations were graphed (H). Statistical significance was calculated using a Student's t-test. P-values less than 0.0001 are indicated with an asterisk. Cultures that were untreated (I) or treated with IGF-I (J) or FGF2 (K) for 24 h were then incubated with BrdU for 2.5 h. BrdU was detected by immunofluorescence. The percentage of BrdU positive cells was calculated and the means and standard deviations were graphed (L). Treatment with IGF increased the total length, hypertrophic area, and incorporation of BrdU into the cultures. Treatment with FGF2 resulted in a reduction in the total length, percentage of hypertrophic cartilage, and incorpration of BrdU into chondrocytes. phosphorylated FGFR3 was detected in untreated cultures whereas cultures treated with TGF-b or FGF2 demonstrated significant phosphorylation of FGFR3 (Fig. 3) . Increased FGFR3 phosphorylation was also detected after 5 days of treatment (not shown). The data together suggest that TGFb acts to regulate development of metatarsal bones at least in part by regulating FGF signaling.
TGF-b regulates the expression of FGF signaling molecules
To determine if TGF-b regulated expression of genes that encode FGF signaling proteins, RNA was extracted from metatarsal bones that were untreated or treated with TGF-b for 24 h. Expression levels of FGF2 and FGF18 mRNA were determined using semi-quantitative RT-PCR (Fig. 4) . FGF18 has been detected in the perichondrium of developing bones and is thought to act in a paracrine manner through FGFR3 on chondrocytes (Liu et al., 2002; Ohbayashi et al., 2002) . FGF2 is also expressed in skeletal elements. The specified gene and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were amplified from cDNA generated from RNA extracted from untreated and TGF-b treated metatarsal cultures. GAPDH was used to control for the amount and quality of RNA used in each reaction. PCR amplification was performed for a varying number of cycles Fig. 2 . The role of the perichondrium in IGF-I and FGF2 activity. The perichondrium was enzymatically removed from metatarsal bones that were then left untreated (A) or were treated with 100 ng IGF-I/ml (B) or 100 ng FGF2/ml (C). After 5 days in culture the total length (D) and the percentage of the clear area representing hypertrophic cartilage (E) were measured. The means and standard deviations were determined and graphed. Statistical significance was calculated using a Student's t-test. P-values less than 0.0001 are indicated with an asterisk. Signaling by IGF-I and FGF2 are not dependent on the perichondrium. Fig. 3 . Effects of TGF-b on IGF and FGF receptor activation. Proteins were isolated from untreated bones (U) and bones treated with 10 ng TGF-b1/ml (b) or 100 ng IGFI/ml or 100 ng FGF2/ml (C). Proteins were used in a straight Western blot for phosphorylated IGF receptor 1 (PO4-IGFR) and total IGF receptor 1 b subunit (IGFR). For FGFR3, proteins were immunoprecipitated with an antibody to FGFR3, run on a gel, and Western blot was performed with a phosphotyrosine specific antibody (PO4-FGFR3). The blot was then stripped and incubated with an FGFR3 antibody (FGFR3). Treatment with TGF-b resulted in an increase in the amount of PO4-FGFR3 without and increase in total FGFR3 levels. Fig. 4 . Gene expression in metatarsal bones treated with TGF-b. RNA was isolated from metatarsal bones in culture that had been left untreated (0) or were treated with 10 ng TGF-b1/ml (C) for 24 h. cDNA was generated from the RNA and used in semi-quantitative PCR amplification. FGF2, FGF18, and glyceraldehyde-3-phosphate dehydrogenase (G, Gapdh) were amplified for varying numbers of cycles (20-45 cy). Gapdh was used to control for the amount of RNA used. Samples run in the absence of reverse transcriptase (RT-) were used to control for the presence of DNA contamination in the samples. Molecular weight markers are shown (M). To quantify changes in gene expression, band intensity measurements were made using Kodak gel imaging software from two separate experiments. After normalization, treatment with TGF-b resulted in FGF18 mRNA levels that were 3.8-and 14.2-fold above the control. FGF2 was regulated 1.4-and 1.7-fold above the untreated control.
to determine the linear range for PCR product formation. Band intensities were determined using Kodak software. Intensities were normalized to the intensity of the GAPDH bands so that normalized fold-differences in gene expression in untreated and treated tissue could be determined. Treatment with TGF-b resulted in a dramatic increase in the levels of FGF18 mRNA (3.8-and 14.2-fold induction in two separate experiments). FGF2 was only marginally regulated by TGF-b (1.4-and 1.7-fold induction in two experiments). The data suggest that TGF-b can modulate the FGF pathway by regulating expression of important mediators of signaling.
FGF18 regulates proliferation and differentiation in organ cultures
Since FGF18 was identified as being regulated by TGFb, the effects of FGF18 on development of the organ cultures was investigated (Fig. 5) . Two dose response experiments were performed ( Fig. 5 and data not shown). Doses between 10 and 600 ng FGF18/ml were tested. Treatment with 200 ng FGF18/ml for 5 days resulted in a decrease in the total bone length that was significant (P!0.05). Higher doses resulted in only marginal further decreases in length (Fig. 5B) . The area of hypertrophic cartilage was also reduced after treatment for 5 days with 50 ng FGF18/ml. Higher doses resulted in significant further reductions in hypertrophic differentiation ( Fig. 5C and data not shown). It has been shown that FGF18 binds with high affinity to FGFR3 that is expressed on proliferating chondrocytes (Xu et al., 2000) . Treatment with 200 ng FGF18/ml for 24 h resulted in decreased chondrocyte proliferation as measured by the incorporation of BrdU (Fig. 5D,E) . The level of inhibition was comparable to that observed with TGF-b in the same experiment (Fig. 5D,E) . In addition, like TGF-b, FGF18 increased proliferation in the perichondrium (Fig. 5D) . The results suggest that FGF18 is sufficient to regulate the proliferation and differentiation of chondrocytes in mouse metatarsal bones. This observation, in addition to regulation of FGF18 mRNA by TGF-b supports a model in which TGF-b may act through FGF18 in the perichondrium to regulate chondrocyte proliferation and/ or differentiation.
FGF inhibitors alter TGF-b responsiveness
To determine if FGF signaling is required for some of the effects of TGF-b on metatarsal development, cultures were treated with inhibitors of FGF activity followed by treatment with TGF-b. The inhibitors used were PSS [poly(4-styrenesulfonic acid)] (Liekens et al., 1999) and a 16mer inhibitory peptide that mimics the conformation of the receptor binding domain of FGF2 but has no sequence homology to FGF2 (Cosic et al., 1994) . PSS binds to FGF at the heparin binding domain and prevents binding to the receptor and heparin sulfate proteoglycans. This compound has been used to block FGF signaling in lens organ cultures (Cerra et al., 2003) . First, the efficacy of the inhibitors to block signaling by FGF2 and FGF18 in organ cultures was tested (Figs. 6 and 7 ). Cultures were either left untreated or treated with the indicated inhibitors overnight at which time half of the cultures were treated with FGF2 or FGF18 for 5 days. The total length of the bones (Figs. 6B and 7B ) and the area of hypertrophic cartilage (Figs. 6C and 7C) were measured. The mean, standard deviation, and significance were calculated and graphed. The inhibitors alone had an effect on metatarsal development. PSS treatment resulted in increased length and hypertrophy. The 16mer peptide resulted in a slight decrease in length and hypertrophy. These effects may be due to blocking different endogenous FGF signaling pathways. Treatment with FGF2 or FGF18 alone resulted in a statistically significant decrease in the total length and the percentage of the bone that contained hypertrophic cartilage, as expected from our previous experiments. In the presence of PSS, treatment with FGF2 or FGF18 resulted in a similar statistically significant decrease in length suggesting PSS does not block the signaling pathway used by FGF2 or FGF18 that affects total bone length (Figs. 6B and 7B ). In contrast, the presence of PSS blocked the ability of FGF2 and FGF18 to inhibit hypertrophic differentiation (Figs. 6C and 7C ). In the presence of the 16mer peptide, total length was not significantly inhibited by FGF2 or FGF18 suggesting that this inhibitor blocks the signaling pathways used by FGF to regulated total bone length (Figs. 6B and 7B ). The presence of the 16mer peptide partially blocked or blocked the effects of FGF2 and FGF18, respectively, on hypertrophic differentiation. In the absence of the inhibitor, the area of hypertrophic cartilage was reduced to 37 or 67% of control after treatment with FGF2 and FGF18, respectively. In the presence of the inhibitor, the area of hypertrophic cartilage was reduced to 63 or 79% of the control after FGF2 or FGF18 treatment, respectively. The results suggest that the 16mer inhibitor can block or at least partially block the signaling pathways used by FGF2 and FGF18 that regulate both growth and hypertrophic differentiation.
Next, cultures were either untreated or pretreated with PSS or the 16mer peptide followed by treatment with TGF-b (Fig. 8) . As expected, treatment with TGFb in the absence of inhibitors resulted in a decrease in the area of hypertrophic cartilage. Treatment with PSS blocked most of the effects of TGF-b on hypertrophic differentiation. In the absence of the inhibitor, the area of hypertrophic cartilage after treatment with TGF-b was 58% the level of the untreated control (Fig. 8C) . In the presence of PSS, the area of hypertrophic cartilage was reduced after treatment with TGF-b to 88% the level of the untreated control. The presence of the 16mer peptide partially blocked the effects of TGF-b on hypertrophic Fig. 5 . Effects of FGF18 on metatarsal development. (A) Whole mount appearance of bones untreated (control), treated with 200 ng FGF18/ml, or 600 ng FGF18/ml, for 5 days. The black bars along the bones mark the central clear area of hypertrophic cartilage. The total length (B) and percent hypertrophic area (C) of the bones was calculated and graphed. Statistical significance was determined using Student's t-test. Statistical significance relative to the untreated control is indicated with an asterisk. P-values are indicated on the graph. FGF18 inhibited total length and hypertrophic differentiation in the metatarsal cultures. (D) Bones that were either untreated (control) or treated with 200 ng/ml FGF18 or 10 ng/ ml TGF-b1 for 24 h were incubated with BrdU for 2.5 h. BrdU incorporation was measured by immunofluourescence. The percentage of BrdU positive chondrocytes was calculated and graphed (E). The standard deviation and statistical significance are shown. FGF18 inhibited chondrocyte proliferation. differentiation (Fig. 8C) . In the absence of the inhibitor, TGF-b inhibited hypertrophic differentiation to 49% the level seen in the untreated control. In the presence of the 16mer peptide hypertrophic differentiation was reduced to only 75% the level of control without TGF-b. The results suggest that the FGF inhibitors, PSS and the 16mer peptide, block or partially block the signaling pathway used by TGF-b to regulate hypertrophic differentiation. Since the drugs also block the effects of FGF2 and FGF18 on hypertrophic differentiation, we propose that part of the effects of TGF-b on hypertrophic differentiation are mediated through FGF.
Treatment with TGF-b in the absence of inhibitors resulted in a decrease in the overall length of the bone as previously reported (Fig. 8B) . Total length was not significantly altered after treatment with TGF-b in the presence of the PSS inhibitor suggesting PSS blocked the effects of TGF-b on length. However, since PSS did not affect the signaling pathways used by FGF2 or FGF18 that regulate total bone length, it is not clear if this effect of TGF-b is mediated through FGF2 or FGF18. Furthermore, in the presence of the 16mer peptide, TGF-b significantly inhibited bone length albeit to a lesser degree than that seen in the absence of the peptide (Fig. 8B ). The 16mer peptide was able to more completely block the effects of FGF2 and FGF18 on bone length suggesting FGF may only partially mediate the effects of TGF-b on bone length.
Discussion
TGF-b1 inhibits hypertrophic differentiation and chondrocyte proliferation by a perichondrium dependent mechanism in embryonic metatarsal cultures (Alvarez et al., 2001; Alvarez et al., 2002) . We proposed IGF and/or the Fig. 6 . Effects of FGF inhibitors on the FGF2 response. (A) Bones were untreated or pretreated with PSS or the 16mer peptide inhibitor followed by treatment with 0 or 100 ng FGF2/ml. After 5 days, total bone length (B) and hypertrophic area (C) were measured. The means and standard deviations were calculated and graphed. Statistical significance was calculated using a Student's t-test. P-values are indicated on the graph. A single asterisk represents significance relative to the 0 FGF2 control of the sample treated with the same drug. A double asterisk indicates significance relative to the control without drug and without FGF2. The dark lines next to the bones marks the clear area representing the hypertrophic zone.
FGF systems as the possible targets of TGF-b1 in the perichondrium. We established that IGF-I and FGF2 can regulate chondrocyte growth and differentiation in the embryonic metatarsal cultures independent of the perichondrium. To test the hypotheses that TGF-b1 either down regulates the IGF system and/or up regulates the FGF system, we looked at IGFR1 and FGFR3 phosphorylation after treatment with TGF-b. FGFR3 phosphorylation was increased after TGF-b treatment but no change in IGFR1 phosphorylation was observed. We then focused on FGF signaling. The inhibition of FGF signaling by pretreatment with FGF inhibitors was used to access the requirement for FGF signaling in the TGF-b response. The results suggested that TGF-b1 regulates endochondral bone formation in culture at least in part through activation of FGF signaling. We also showed that TGF-b stimulates expression of FGF18 mRNA making it a likely target for TGF-b in the perichondrium.
During endochondral bone formation, the perichondrium is involved in signaling pathways which negatively regulate chondrocyte proliferation and differentiation (Di Nino et al., 2001; Long and Linsenmayer, 1998) , including Ihh and TGF-b signaling (Alvarez et al., 2001 (Alvarez et al., , 2002 Long et al., 2001 ). In contrast, we found that both IGF-I and FGF2 can regulate chondrocyte growth and differentiation even in the absence of the perichondrium. The treatment of metatarsal organ cultures with IGF-I resulted in an increase in total bone length and hypertrophic differentiation while treatment with FGF2 caused a decrease in bone length and hypertrophic differentiation, both in the presence and the absence of the perichondrium. Both IGF-I and IGF-II, and many FGF ligands, most notably FGF18, (Beck et al., 1988; Han et al., 1987; Liu et al., 2002; Ohbayashi et al., 2002; Van Kleffens et al., 1998) are known to be expressed in the perichondrium during endochondral bone formation Fig. 7 . Effects of FGF inhibitors on the FGF18 response. (A) Bones were untreated or pretreated with PSS or the 16mer peptide inhibitor followed by treatment with 0 or 200 ng FGF18/ml. After 5 days, total bone length (B) and hypertrophic area (C) were measured. The means and standard deviations were calculated and graphed. Statistical significance was calculated using a Student's t-test. P-values are indicated on the graph. A single asterisk represents significance relative to the 0 FGF18 control of the sample treated with the same drug. A double asterisk indicates significance relative to the control without drug and without FGF18. The dark lines next to the bones marks the clear area representing the hypertrophic zone.
and it is possible that they are mediating the perichondrium dependent effects of TGF-b.
FGF signaling has been shown to play a critical role in the regulation of bone growth. FGFR3 is expressed in proliferating and prehypertrophic chondrocytes in the epiphyseal growth plates Ohbayashi et al., 2002; Peters et al., 1993) . It has been shown that expression of activating Fgfr3 mutants in mice results in dwarfism (Coumoul and Deng, 2003) . In contrast, lack of Fgfr3 in mice causes skeletal overgrowth, indicating that FGFR3 signaling inhibits endochondral bone growth (Colvin et al., 1996; Deng et al., 1996) , making FGF signaling a likely candidate for mediating the inhibitory effects of TGF-b during endochondral bone formation. The relationship between TGF-b and FGF signaling during endochondral bone formation was explored in this study.
The results show that TGF-b increases FGF18 mRNA levels and FGFR3 phosphorylation in the organ cultures, suggesting that TGF-b1 may be targeting perichondrial FGF ligands that in turn activate FGFR3, which is known to inhibit chondrocyte proliferation and differentiation.
Recent work has suggested that FGF18 is the endogenous ligand of FGFR3 in prehypertrophic chondrocytes (Liu et al., 2002; Ohbayashi et al., 2002) , and the expression of FGF18 in the perichondrium has also been reported (Liu et al., 2002; Ohbayashi et al., 2002) making it a possible perichondrial target for TGF-b1. In our studies, TGF-b1 increases expression of FGF18 mRNA. Recent genetic studies have identified a defect in chondrogenesis and osteogenesis in mice lacking Fgf18 similar to that seen in the Fgfr3 mutant mice (Liu et al., 2002; Ohbayashi et al., 2002) . Our study demonstrated that treatment of the Fig. 8 . Effects of FGF inhibitors on TGF-b response. Metatarsal bones were treated with PSS or with two concentrations of a 16mer inhibitor. They were then treated with TGF-b1 and the bones were photographed after 5 days and total bone length (B) and hypertrophic area (C) were measured. The means and standard deviations were calculated and graphed. Statistical significance was calculated using a Student's t-test. P-values are indicated on the graph. A single asterisk represents significance relative to the 0 TGF-b control of the sample treated with the same drug. A double asterisk indicates significance relative to the control without drug and without TGF-b. PSS and, to a lesser extent, the higher concentration of the 16mer partially blocked the inhibitory effects of TGF-b on the total length and hypertrophic area observed in the cultures. The dark lines next to the bones marks the clear area representing the hypertrophic zone. PSS and the 40 nM concentration of the 16mer peptide were tested in separate experiments. metatarsal organ cultures with FGF18 also results in inhibition of chondrocyte proliferation and hypertrophic differentiation, similar to treatment with FGF2, another ligand for FGFR3.
We used two inhibitors of FGF signaling to determine if there was a functional connection between TGF-b and FGF signaling in endochondral bone formation. The first inhibitor, PSS, is a heparin-mimicking polysulfonated compound (Liekens et al., 1999) . It was shown to inhibit binding of FGF2 to heparin sulfate proteoglycans, abrogating the FGF/ proteogylcan and receptor complex. PSS has been used in cell culture and organ culture models to block the effects of FGF2 on specific biological processes (Cerra et al., 2003; Liekens et al., 1999) . The second inhibitor used was a novel 16mer peptide that was developed through resonant recognition modeling (Cosic et al., 1994) . The peptide has conformational similarity to the receptor-binding domain of FGF2 but has no sequence homology. It has been shown to block FGF2 binding to FGFR1 and inhibit FGF2 induced proliferation in fibroblasts and human glioma cells (Cosic et al., 1994; Kono et al., 2003) . Both inhibitors have been characterized with regards to FGF2 and it's high affinity receptor FGFR1. It was not clear if the inhibitors would have the same efficacy against FGF2 and FGF18 signaling in metatarsal organ cultures. In the present study, we showed that both inhibitors are able to block specific effects of FGF2 and FGF18. PSS blocked the effects of both FGF2 and FGF18 on hypertrophic differentiation but did not block the effects on total bone length. The result suggests there may be differences in the way FGF regulates proliferation versus differentiation. It has been suggested in a recent study that during FGFR3 signaling in bone growth, the MAPK pathway mediates inhibition of hypertrophic chondrocyte differentiation, whereas Stat1 mediates inhibition of chondrocyte proliferation (Murakami et al., 2004) . In contrast to PSS, the 16mer peptide blocked the effects of FGF2 and FGF18 on total bone length but only partially blocked the effects on hypertrophic differentiation. In addition, treatment with the inhibitors alone had and effect on development of the metatarsals. Treatment with PSS resulted in longer bones with more hypertrophic differentiation while treatment with the 16mer peptide resulted in shorter bones with less hypertrophic differentiation. The effects of the inhibitors alone likely represent the blocking of various endogenous FGF signaling pathways. It also illustrates one of the caveats of drug studies, which is that the exact specificity of the drug in a particular system is difficult to determine.
In the present study PSS and the 16mer peptide blocked and partially blocked, respectively, the effects of TGF-b on hypertrophic differentiation. The drugs had similar effects on TGF-b and FGF-mediated inhibition of hypertrophic differentiation. We interpret this result to mean that that FGF is at least partially required to mediate the effects of TGFb on hypertrophic differentiation. As mentioned above, the specificity of PSS has not been clearly established and we cannot rule out the requirement of additional heparinbinding growth factors required for the TGF-b response. Such a factor could be required for TGF-b mediated effects on bone length which, were blocked by PSS under conditions in which the effects of FGF on bone length were not affected. Likewise, the partial block of TGF-b effects on bone length with the 16mer peptide suggest that additional factors may be required for the TGF-b mediated reduction in bone length.
As TGF-b has been shown to regulate expression of IGFs, IGF receptor, and IGFBPs in many cell types including chondrocytes (de Los Rios and Hill, 2000; Kveiborg et al., 2001; Tsukazaki et al., 1994) , we also investigated whether TGF-b1 regulates activation of the IGF receptor in embryonic growth plate. We did not detect alterations in IGFR phosphorylation after treatment with TGF-b. A lack of change in receptor phosphorylation does not necessarily mean a lack of an effect. Receptors in cells that are not targets of TGF-b could drown out any effects of TGF-b on a subset of receptors, thus, any co-ordination between TGF-b and IGF signaling needs to be investigated further.
In conclusion, the study shows that both IGF-I and FGF2 have perichondrium independent effects on chondrocyte proliferation and differentiation and that TGF-b interacts with components of FGF signaling during endochondral bone formation. Our results suggest that FGF ligands, perhaps FGF18, modulate some of the perichondriumdependent inhibitory effects of TGF-b1 during endochondral bone formation. FGF 18 and/or FGFR-3 knock out mouse models can be used to enable further studies aimed at understanding co-ordination of TGF-b and FGF18 signaling specifically. Investigating the complex interaction between TGF-b and FGF systems, which are key regulators of skeletal development, will enhance our understanding of the process of endochondral bone formation immensely.
Materials and methods

Embryonic metatarsal rudiment organ culture
The three central metatarsals from the hind limbs of day E15.5 mouse embryos were removed and placed in culture as previously described (Dieudonne et al., 1994; Serra et al., 1999) . For experiments to remove the perichondrium, metatarsals from one limb were stripped of the perichondrium while those from the contralateral limb were kept intact. Collagenase type 2, 1 mg/ml in PBS (Worthington biochemical Corp.), was used to remove the perichondrium, as previously reported (Haaijman et al., 1999; Thesingh and Burger, 1983) . Enzymatic activity was stopped by transferring the bones to 10% Fetal Bovine Serum in PBS and the remaining perichondrium was removed mechanically by rolling on a plastic surface. All rudiments were cultured in 24-well plates in 1 ml of medium containing alpha-MEM (Gibco-BRL) supplemented with 0.05 mg/ml ascorbic acid, 0.3 mg/ml L-glutamine, 0.05 mg/ml gentamycin, 1 mM b-glycerophosphate, and 0.2% Bovine Serum Albumin (BSA). Explants were grown at 37 8C in a humidified 5% CO 2 incubator. IGF-1 (GroPep, Australia), FGF2 or FGF18 (R&D Systems, MN or US Biologicals), or TGF-b1 (R&D Systems, MN) were added to cultures 12-16 h after dissection. Inhibitors PSS [poly(4-styrenesulfonic acid)], MWZ70,000, (PolySciences,) and a 16mer inhibitory peptide (Bachem, #H2176) were added within a few hours after the dissection and TGF-b was added the next morning. Cultures were observed and photographed with an Olympus SZH12 dissecting microscope after 5 days of treatment. Cultures were fixed in fresh 4% paraformaldehyde in PBS overnight at 4 8C then the cultures were dehydrated through a series of ethanols and xylene and embedded in paraffin. Sections (5 mm) were stained with hematoxylin and eosin or used for immunodetection of BrdU incorporation and for in situ hybridization.
The length of bones was calculated after 5 days of treatment by measuring the length of each metatarsal in photographs taken with an Olympus SZH12 dissecting microscope with a Magnafire digital camera. The total length was measured in photographs that were all taken at the same magnification (25!). The actual bone length was calculated by dividing the length measured on the images by the magnification indicated on the microscope and camera. The mean, standard deviation, and significance were determined using a Student's t-test calculated with Microsoft Excel. Groups with a probability value less than 0.05% (P!0.05) were considered significantly different.
The percent of the bone rudiment containing hypertrophic cartilage was calculated after 5 days of treatment by three separate methods: (1) Measuring the total length of the bone rudiment and the length of the 'clear' area on whole bones (Alvarez et al., 2001; Dieudonne et al., 1994) . (2) Measuring the histologically hypertrophic area in hematoxylin and eosin stained sections and/or (3) Measuring the area of the bone culture containing Type X collagen (Col10a1) mRNA after in situ hybridization. Measurements were taken from photographs from a SZH12 dissecting microscope for pictures of whole bones or an Olympus BX-51 upright microscope for pictures of sections. The percent of the total cartilage that was hypertrophic was calculated as: (length of hypertrophic zone/total length)!100. The mean and standard deviation was calculated for each group. Significant differences were determined using the Student's t-test. Significantly different results were indicated by P!0.05.
BrdU labeling
Metatarsal bones were untreated or treated with IGF-1, FGF2, or FGF18 for 24 h followed by treatment with 10 mM BrdU (Boehringer Mannheim) for 2.5 h as previously described (Alvarez et al., 2001) . Metatarsal rudiments were then washed twice in PBS at 37 8C, fixed in paraformaldehyde at 4 8C overnight, embedded in paraffin, and cut into 5-mm sections. Sections were deparaffinized, denatured in 2 N HCl for 20 min at 37 8C, and neutralized in 1% boric acid/0.0285% sodium borate, pH 7.6. Next, the sections were treated with 0.005 mg trypsin/ml 0.05 M Tris, pH 7.6, for 3 min at 37 8C and washed three times in PBS. Immunostaining was then performed using Vectastain Elite staining kit (Vector Laboratories) as described by the manufacturer. A rat mAb directed to BrdU (Harlan) was used as the primary antibody at a 1:200 dilution. Cy3-conjugated avidin (Vector Laboratories) was substituted for the avidinbiotin-peroxidase complex in the Vector Elite kit. Excess Cy3-conjugated avidin was removed from the sections by washing three times for 10 min each in PBS at room temperature. The nuclei were counterstained with YoPro (Molecular Probes), washed, and immediately mounted with Aquapoly mount (Poly Sciences). Fluorescence was observed and imaged using an Olympus BX-51 upright microscope with a Magnafire digital camera and Photoshop software. BrdU postive and negative cells were counted in a 400! field of cells about halfway between the hypertrophic area and the end of the bone at both ends of each bone. Thus, two fields were counted in each of three to four bones under each condition. Perichondrium and hypertrophic cells were excluded. The percentage of labeled nuclei for each field was calculated as the number of red, BrdU stained cells over the total number of cells (redCgreen) in the field multiplied by 100. The mean, standard deviation, and P-values were determined using Microsoft Excel.
Semi-quantitative RT-PCR
RNA was extracted from cartilage cultures by lysis in guanidine thiocyanate using the Ambion RNaqueous kit (Cat# 1912; (Austin, TX) ) and the manufacturers instructions with the modification that the cartilage rudiments were first homogenized in the guanidine solution in a microcentrifuge tube with a small pestle. RNA was treated with RNase free DNase (Promega, Madison, WI) for 1 h at 37 8C, phenol:-chloroform extracted, and ethanol precipitated. Precipitation of RNA was facilitated with 20 mg glycogen per sample (Boehringer Mannheim). RNA concentration was determined spectrophotometrically. For RT-PCR analysis, cDNA was synthesized from 1 mg of total RNA using oligo dT primers using standard protocols (Curent Protocols in Molecular Biology, Wiley). For each sample 5 ml cDNA was amplified with 0.2 mM primers and 0.2 mM nucleotides for varying cycles (15-45 cycles). Samples incubated without reverse transcriptase were used to determine if there was DNA contamination in the RNA samples. GAPDH was used as an internal control for the amount of cDNA used in each reaction. The marker is the 100 bp ladder from In Vitrogen. Band intensity was determined using Kodak 1D software and the Kodak gel imaging system. Band intensities were normalized to GAPDH and the fold-change in gene expression with and without TGF-b was determined. Primer sequences and conditions used are shown in Table 1 .
Immunoprecipitation and immunoblotting
After the indicated time in culture the bones were transferred to standard RIPA buffer and homogenized. The amount of protein was quantified using the Biorad protein assay and 1 mg of protein was immunoprecipitated using an anti-FGFR3 antibody (Santa Cruz Biologicals, CA, #SC-123) or anti-IGFR1 antibody (Oncogene Science, #GR11T) and protein G conjugated agarose (Sigma, MO) overnight at 4 8C. The extracts were centrifuged at 15,000 rpm for 15 min and the pellets were washed with the lysis buffer three times. The pellet was resuspended in standard denaturing sample buffer, heated in a boiling water bath for 3 min then run on a 7% SDS-polyacrylamide gel. The protein was transferred to nitrocellulose membranes (BIORAD) and incubated with anti-phosphotyrosine antibody (PY20, Oncogene Science), anti-IGF receptor1 beta antibody (Santa Cruz Biologicals, #sc-713) or anti-FGR3 antibody (Santa Cruz Biologicals #SC-123). The membrane was incubated with the appropriate HRP-conjugated secondary antibody then developed using the ECL kit from Amersham. For Western blots of activated IGFR1, a phospho-specific IGFR1 antibody was used (Cell Signaling, #3021). For straight Western blots, equal amount of protein was loaded into each well. The blots were processed as described (Current Protocols in Molecular Biology, Wiley).
